失去了双基因酶Bap1触发了抗瘤免疫力
Hong Chang1, Mingxia Li1, Linlin Zhang1
1Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, 1239 Siping Road, Shanghai, 200092, China.
癌细胞中Bap1的损失通过激活CD8+T细胞来增强抗瘤免疫力,为癌症免疫疗法提供了一个新的点. 这一发现有助于更好地理解免疫逃避和抗癌治疗中的抵抗.
科学领域:
- 癌症免疫学 癌症免疫学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 瘤微环境是一个微环境.
背景情况:
- 癌症免疫疗法,特别是PD-L1阻断,显示出有限的疗效和频繁的抗药性.
- 了解癌症免疫逃避和抵抗机制对于改善治疗结果至关重要.
研究的目的:
- 为了确定PD-L1表达和癌症免疫规避的调节者.
- 研究Bap1在抗瘤免疫中的作用及其作为治疗点的潜力.
主要方法:
- 基因组规模的CRISPR-Cas9查,以确定Bap1作为PD-L1调节器.
- 使用小鼠模型进行体内研究,以评估瘤生长和存活率.
- 流细胞计,RNA-seq和CUT&Tag-seq用于分析瘤特征.
- 通过TCGA数据分析,将BAP1表达与人类癌症中的免疫特征相关联.
主要成果:
- 失去Bap1激活了CD8+T细胞依赖的抗瘤免疫力.
- 删除Bap1会增加抗瘤免疫基因,减少免疫逃避基因.
- 瘤微环境显示cDC1和CD8+T细胞增加,中性粒细胞和Tregs减少.
- 瘤消除取决于MHCI和Fas介导的CD8+T细胞细胞毒性.
- 在人类癌症中,BAP1表达与DC激活和T细胞细胞毒性标志相反相关.
结论:
- Bap1 作为抗瘤免疫的关键调节剂.
- Bap1是一种潜在的生物标志物,用于免疫治疗的癌症患者分层.
- 针对Bap1提供了一种新的治疗策略,用于增强癌症免疫疗法.
更多相关视频
11:06Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
Published on: September 20, 2017
09:14Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
Published on: January 14, 2016
相关概念视频
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
The JAK-STAT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
